The content on this site is intended for healthcare professionals only
Dr Ryotaro Nakamura speaks to ecancer about a multi-centre biologic assignment trial comparing reduced intensity allogeneic hematopoietic cell transplantation to hypomethylating therapy or best supportive care in patients aged 50-75 with advanced myelodysplastic syndrome: blood and marrow transplant clinical trials network study.
This study was presented at ASH 2020 virtual conference.
Dr Nakamura initially speaks about the rationale behind the study and the method in which this study was conducted.
He then explains some of the key results from this study and talks about the future impact that these results can have on the treatment of patients with advanced myelodysplastic syndrome.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
A patient-reported questionnaire may eliminate the need for an ophthalmic exam before belantamab mafodotin dosing in TI NDMM
Importance of MRD in newly developed multiple myeloma
Isatuximab shows benefit in transplant-ineligible patients with newly diagnosed multiple myeloma
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
Manageable safety profile with early efficacy of Tec-DR in NDMM
Treatment of multiple myeloma in Turkey
Melflufen and dexamethasone versus pomalidomide and dexamethasone in relapsed refractory multiple myeloma
